Innovative Drug Development in Dermatology
Latest News

September 24, 2014

Brickell Announces Positive Preliminary Results of a Pilot Clinical Study of BBI-4000 for the Treatment of Hyperhidrosis and welcomes Charlie Stiefel and Bill Ju to Board of Directors.
Read Article (PDF)

June 30, 2014

Brickell announces licensing agreement for its novel retinoid therapy, BBI-3000, with Merz North America.
Read Article (PDF)

Focused on the development of novel therapies for the treatment of skin diseases.

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative, first-in-class therapeutics to satisfy current unmet human needs in the global dermatology markets.



Brickell Biotech, Inc. © 2014 All Rights Reserved.